Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 7747.

https://doi.org/10.1182/blood-2024-199041

Published: 2024

Journal Articles

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2024-199074

Published: 2024

Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

Filippo Bagnoli, Jacopo Calabrese De Feo, Francesca Livia Letizia Ricci, Jacopo Mariotti, Barbara Sarina, Monica Balzarotti, Daniela Taurino, Daniele Mannina, Chiara De Philippis, Daoud Rahal, Arturo Bonometti, Massimo Magagnoli, Rita Mazza, Marcello Rodari, Laura Giordano, Stefania Bramanti, Carmelo Carlo-Stella, Armando Santoro

Blood (2024) 144 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2024-203287

Published: 2024

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors

Anna Dodero, Stefania Bramanti, Martina Pennisi, Silva Ljevar, Annalisa Chiappella, Massimo Magagnoli, Anna Guidetti, Francesco Corrado, Paulina Nierychlewska, Alice Di Rocco, Antonello Domenico Cabras, Daoud Rahal, Chiara De Philippis, Armando Santoro, Carmelo Carlo-Stella, Paolo Corradini

Blood (2022) 140 (Supplement 1): 9468–9469.

https://doi.org/10.1182/blood-2022-163651

Published: 2022

Journal Articles

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Reid W Merryman, MD, Luca Castagna, MD, Paolo Corradini, MD, Vincent T. Ho, MD, David A. Bond, MD, Samantha Jaglowski, MDMPH, Michael A Spinner, Sally Arai, MD, Robert Lowsky, MD, Alex F. Herrera, MD, Anna Guidetti, MD, Geoffrey Shouse, DO, PhD, Didier Blaise, MD PhD, Jean Marc Schiano De Colella, MD, Talha Badar, MD, Mehdi Hamadani, MD, Stephen M Ansell, MD PhD, Yago Nieto, MD PhD, Chloe Spilleboudt, MD, Tatyana A. Feldman, MD, Lori Dahncke, BSN, Anurag K. Singh, MD, Joseph P. McGuirk, DO, Mohamad Mohty, MD PhD, Remy Dulery, MD, Aspasia Stamatoulas Bastard, Roch Houot, MD PhD, Guillaume Manson, MD, Marie-Pierre Moles, MD, Corentin Orvain, MD, Kamal Bouabdallah, MD, Matthew J. Frigault, MD, Yi-Bin Chen, Ryan C. Lynch, MD, Stephen D. Smith, MD, Uttam Rao, MD, Michael T Byrne, DO, Jason Romancik, MD, Jonathon B. Cohen, MDMS, Robin M. Joyce, MD, Maryam Rahimian, MD, Asad Bashey, MD PhD, Hatcher J. Ballard, BS, Jakub Svoboda, MD, Laura Giordano, Valter Torri, Beatrice Casadei, MD, Martina Sollini, MD, Chiara De Philippis, MD, Massimo Magagnoli, MD, Armando Santoro, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Carmelo Carlo-Stella, MD

Blood (2019) 134 (Supplement_1): 775.

https://doi.org/10.1182/blood-2019-125039

Published: 2019

Journal Articles

Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 131.

https://doi.org/10.1182/blood-2019-131096

Published: 2019

Journal Articles

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Armando Santoro, MD, Luigina Mollica, MD PhD, Sirpa Leppa, MD Prof, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Maria Dimou, MD PhD, Judit Demeter, MD PhD Dr. Sci, Massimo Magagnoli, MD, Liana Rodrigues, MD, Oliver Wirtz, MSc, Florian Hiemeyer, MSc, Li Liu, PhD, Karl Koechert, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD PhD

Blood (2018) 132 (Supplement 1): 395.

https://doi.org/10.1182/blood-2018-99-116715

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Armando Santoro, MD, Luca Castagna, MD, Massimo Magagnoli, MD, Stefania Bramanti, MD, Jacopo Mariotti, MD, Rita Mazza, MD, Lucia Morello, MD, Francesca Ricci, MD, Barbara Sarina, MD, Chiara De Philippis, MD, Simona Sica, MD, Marcello Rodari, MD, Martina Sollini, MD, Margarita Kirienko, MD, Laura Giordano, Arturo Chiti, MD, Paolo Corradini, MD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2018-99-118127

Published: 2018

Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Blood (2018) 132 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2018-99-115313

Published: 2018

Journal Articles

The Novel Calcium Release-Activated Calcium (CRAC) Channel Inhibitor RP4010 Exerts Potent Antitumor Effects in NOD/SCID/IL2Rg -/- Mice with Diffuse Large B Cell Lymphoma (DLBCL) Cell Line Xenografts

Silvia Laura Locatelli, PhD, Giuseppa Careddu, Massimo Magagnoli, MD, Martina di Trani, Lucia Morello, MD, Srikant Viswanadha, PhD, Swaroop Kumar VS Vakkalanka, PhD, Luca Castagna, MD, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2017) 130 (Supplement 1): 4101.

https://doi.org/10.1182/blood.V130.Suppl_1.4101.4101

Published: 2017

Journal Articles

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

Blood (2017) 130 (Supplement 1): 2777.

https://doi.org/10.1182/blood.V130.Suppl_1.2777.2777

Published: 2017

Journal Articles

RNA Sequencing Reveals Mechanisms Underlying Modulation of Hodgkin Lymphoma Cells and Tumor Microenvironment By the PI3K δ/γ Inhibitor, RP6530

Silvia Laura Locatelli, PhD, Francesca Maria Consonni, PhD, Giuseppa Careddu, Simone Serio, Srikant Viswanadha, PhD, Swaroop Kumar VS Vakkalanka, PhD, Lucia Morello, MD, Massimo Magagnoli, MD, Luca Castagna, MD, Armando Santoro, MD, Antonio Sica, PhD, Carmelo Carlo-Stella, MD

Blood (2017) 130 (Supplement 1): 2476.

https://doi.org/10.1182/blood.V130.Suppl_1.2476.2476

Published: 2017

Journal Articles

Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study

Carmelo Carlo-Stella, MD, Richard Delarue, MD, Prajak J Barde, MD, Lydia Scarfo, Uday Kumar, Srikant Viswanadha, PhD, Silvia Laura Locatelli, PhD, Sara Gandolfi, MD, Valeria Pittari, MD, Lucia Morello, Massimo Magagnoli, Armando Santoro, Andrés J.M. Ferreri, MD

Blood (2016) 128 (22): 3011.

https://doi.org/10.1182/blood.V128.22.3011.3011

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation Followed By Allogeneic SCT Provides Promising Results in Patients with Relapsed DLBCL and Adverse Prognostic Features Compared with ASCT Alone

Roberto Crocchiolo, MD, PhD, Barbara Sarina, MD, Stefania Bramanti, MD, Lucio Morabito, MD, Andrea Rimondo, Monica Balzarotti, Massimo Magagnoli, Carmelo Carlo-Stella, MD, Armando Santoro, MD, Luca Castagna

Blood (2015) 126 (23): 2034.

https://doi.org/10.1182/blood.V126.23.2034.2034

Published: 2015

Journal Articles

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Stefano Sacchi, MD, Samantha Pozzi, MD, Marina Cesaretti, Luigi Marcheselli, MS, Gabriele Buda, MD, Antonio Lazzaro, MD, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, MD, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, MD, Massimo Magagnoli, MD, Franco Silvestris, MD, Pier Paolo Fattori, MD, Patrizia Tosi, MD, Eliana Valentina Liardo, MD, Alessia Bari, MD, Angelo Michele Carella

Blood (2013) 122 (21): 4383.

https://doi.org/10.1182/blood.V122.21.4383.4383

Published: 2013

Journal Articles

Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Stefano Sacchi, Samantha Pozzi, Marina Cesaretti, Luigi Marcheselli, Eliana Valentina Liardo, Gabriele Buda, Antonio Lazzaro, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, Massimo Magagnoli, Franco Silvestris, Pier Paolo Fattori, Patrizia Tosi, Angelo Michele Carella

Blood (2012) 120 (21): 1645.

https://doi.org/10.1182/blood.V120.21.1645.1645

Published: 2012

Journal Articles

Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy

Massimo Magagnoli, Katia Marzo, MD, Monica Balzarotti, Marcello Rodari, Rita Mazza, Laura Giordano, MD, Sara Gandolfi, MD, Stefania Bramanti, Antonella Anastasia, MD, Fabio Romano Lutman, MD, Arturo Chiti, MD, Armando Santoro

Blood (2011) 118 (21): 93.

https://doi.org/10.1182/blood.V118.21.93.93

Published: 2011

Journal Articles

Result of FDG PET Imaging After Chemotherapy +/− Immunotherapy Is a Significant and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: Survey From a Single Institution

Massimo Magagnoli, Rita Mazza, Sara Gandolfi, Marcello Rodari, Laura Giordano, MD, Antonella Anastasia, MD, Egesta Lopci, Arturo Chiti, Armando Santoro, Monica Balzarotti

Blood (2011) 118 (21): 2674.

https://doi.org/10.1182/blood.V118.21.2674.2674

Published: 2011

Journal Articles

Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL)

Massimo Magagnoli, Monica Balzarotti, Antonella Anastasia, Rita Mazza, Laura Giordano, MD, Luca Castagna, Michele Spina, MD, Alessandra Romano, Stefania Bramanti, Armando Santoro

Blood (2010) 116 (21): 1761.

https://doi.org/10.1182/blood.V116.21.1761.1761

Published: 2010

NARROW

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

The Novel Calcium Release-Activated Calcium (CRAC) Channel Inhibitor RP4010 Exerts Potent Antitumor Effects in NOD/SCID/IL2Rg -/- Mice with Diffuse Large B Cell Lymphoma (DLBCL) Cell Line Xenografts

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

RNA Sequencing Reveals Mechanisms Underlying Modulation of Hodgkin Lymphoma Cells and Tumor Microenvironment By the PI3K δ/γ Inhibitor, RP6530

Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study

Autologous Stem Cell Transplantation Followed By Allogeneic SCT Provides Promising Results in Patients with Relapsed DLBCL and Adverse Prognostic Features Compared with ASCT Alone

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy

Result of FDG PET Imaging After Chemotherapy +/− Immunotherapy Is a Significant and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: Survey From a Single Institution

Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only